Eli Lilly has struck a deal to buy genetic-medicine biotechnology company Orna Therapeutics for up to $2.4 billion in cash.

Four drug companies — Agomab Therapeutics, Eikon Therapeutics, Spyglass Pharma, and Veradermics — went public this week, ...

China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the industry—and Washington—are rethinking the risks.

Unprofitable biotech Veradermics, which still needs FDA approval for its hair loss pill, surged on its debut day.

The latest firm to top up its venture capital coffers is Austin, Texas-based Santé Ventures, which on Monday announced its ...

Agomab Therapeutics and SpyGlass Pharma secured a combined $350 million in two separate initial public offerings on Thursday ...

Across all industries, the total number of companies on track to go public could make this week the most active for IPOs ...

Cantai launched in 2023 with a $3 million seed round. The company has raised $6.55 million to date at an undisclosed valuation, according to PitchBook. It develops drug candidates with special ...

Stem cell therapy biotech PrimeGen US is taking the less-traveled special purpose acquisition company (SPAC) route to the ...

Department of Economic & Community Development Commissioner Daniel O'Keefe speaks at the BioCT legislative breakfast in New Haven on Jan. 27, 2025. Monday morning's annual legislative breakfast hosted ...

The companies Aktis Oncology, Alumis, and Parabilis Medicines bagged the biggest biotech funding rounds overall in January ...

A major biotech company has announced plans to lay off more than 100 positions from its Franklin, Massachusetts, facility. According to a Workers Adjustment and Retraining Notification notice, layoffs ...